A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

Recruiting

Phase 3

DiamydA Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

Sponsor:

Diamyd Medical AB

Code:

NCT05018585

Conditions

Type 1 Diabetes Mellitus

Eligibility Criteria

Sex: All

Age: 12 - 28

Healthy Volunteers: Not accepted

Interventions

Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®

Colecalciferol 2000 IU

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-16. This information was provided to ClinicalTrials.gov by Diamyd Medical AB on 2025-04-09.